New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer
The New England Journal of Medicine published Phase 1/2 data on Revolution Medicines' RASONQUE (daraxonrasib) in previously treated RAS mutant non-small cell lung cancer, based on 136 patients in the RMC-6236-001 trial with a July 21, 2025 data cutoff. In the 38 docetaxel-naive patients treated at 160 mg to 220 mg, the confirmed objective response rate was 42% and disease control rate was 89%, with median progression-free survival of 8.3 months and median overall survival of 16.0 months. Grade 3 treatment-related adverse events occurred in 25% of patients, with no Grade 4 or Grade 5 events at these dose levels.
Key figures
- Drug Name
- RASONQUE (daraxonrasib)
- Phase Of Trial
- Phase 1/2
- Dcr
- 89%
- Orr
- 42%
- Dcr 95ci
- 75%-97%
- Orr 95ci
- 26%-59%
- Dose range
- 160 mg to 220 mg
- Data cutoff
- July 21, 2025
- Phase3 trial
- RASolve 301 (NCT06881784)
- Grade3 trae rate
- 25%
- Median os months
- 16
- Median pfs months
- 8.3
- Patients in trial
- 136
- Phase1 2 trial id
- NCT05379985
- Docetaxel naive subgroup n
- 38
- Grade4 5 traes in dose range
- 0
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.